All In Biotech

Drug Trial Radar · NCT04943068

A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 193 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

193

Actual

Start

May 10, 2021

Primary completion

May 16, 2023

Study completion May 16, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).

Conditions

  • Hypoactive Sexual Desire Disorder

Interventions

  • BremelanotideDrug

    Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.

  • PlaceboDrug

    Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to End of Study in the desire domain from the FSFITime frame: Baseline up to End of Study(8weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.